trending Market Intelligence /marketintelligence/en/news-insights/trending/dlh6h0hfdxm6ouncgtk9lw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's revises outlook on Shire to positive

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Moody's revises outlook on Shire to positive

Moody's affirmed Shire PLC's Baa3 issuer rating.

The rating agency revised the outlook on the rating to positive from stable, representing its expectations for solid operating performance from recent product launches and continuing debt reduction.

Moody's said the Baa3 rating reflects the company's $15 billion revenue base and its strong placement in the market in the fields of hemophilia, immunology, and neuroscience.

The agency believes the Irish company's focus on products that treat rare diseases is positive. Drugs for such conditions are expensive, critical for patients and have very high barriers to entry, according to Moody's.